Literature DB >> 6365781

Functions of human neutrophilic granulocytes after in vivo exposure to interferon alpha.

S Einhorn, C Jarstrand.   

Abstract

The ability of neutrophilic granulocytes to phagocytize yeast particles and to reduce Nitro Blue Tetrazolium at rest and on activation with bacterial stimuli was monitored in 32 patients receiving treatment with human interferon alpha. The ability of these cells to attach to and ingest yeast particles was not altered to any major extent during 1 year of interferon treatment. In most patients, the Nitro Blue Tetrazolium-reducing activity increased after the first injection of interferon. During prolonged treatment with interferon alpha, 1 week to 1 year, granulocytes activated with bacteria exhibited a reduced Nitro Blue Tetrazolium activity in most patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6365781      PMCID: PMC264292          DOI: 10.1128/iai.43.3.1054-1057.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  RECOVERY OF AN INTERFERON-LIKE SUBSTANCE FROM CEREBROSPINAL FLUID.

Authors:  I GRESSER; K NAFICY
Journal:  Proc Soc Exp Biol Med       Date:  1964-10

2.  CIRCULATING INTERFERON-LIKE VIRAL INHIBITOR IN PATIENTS WITH MENINGITIS DUE TO HAEMOPHILUS INFLUENZAE.

Authors:  R H MICHAELS; M M WEINBERGER; M HO
Journal:  N Engl J Med       Date:  1965-06-03       Impact factor: 91.245

3.  Interrelationships of viral, mycoplasmal, and bacterial agents in uncomplicated pneumonia.

Authors:  M L Lepow; N Balassanian; J Emmerich; R B Roberts; M S Rosenthal; E Wolinsky
Journal:  Am Rev Respir Dis       Date:  1968-04

4.  Production of interferon by human leukocytes in vitro.

Authors:  H Strander; K Cantell
Journal:  Ann Med Exp Biol Fenn       Date:  1966

5.  Interferon production in human mumps infections.

Authors:  D J Waddell; J R Wilbur; T C Merigan
Journal:  Proc Soc Exp Biol Med       Date:  1968-01

6.  Interferon enhances NBT-reduction and phagocytosis by human monocytes.

Authors:  C Jarstrand; S Einhorn
Journal:  J Clin Lab Immunol       Date:  1981-11

7.  Influence of human interferon-alpha therapy on cytotoxic functions of blood lymphocytes. Studies on lectin-dependent cellular cytotoxicity, antibody-dependent cellular cytotoxicity, and natural killer cell activity.

Authors:  S Einhorn; H Blomgren; H Strander; J Wasserman
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  Effect of interferon on human neutrophilic granulocytes.

Authors:  C Jarstrand; S Einhorn
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  The interferon system in patients with malignant disease.

Authors:  T Hahn; S Levin
Journal:  J Interferon Res       Date:  1982

10.  In vitro and in vivo effects of interferon on the response of human lymphocytes to mitogens.

Authors:  S Einhorn; H Blomgren; N Einhorn; H Strander
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

View more
  5 in total

1.  Influence of alpha-interferon therapy on blood lymphoid cells. Studies on antibody production, mixed lymphocyte culture response, mitogen responsiveness and 2'-5'oligoadenylate synthetase activity.

Authors:  S Einhorn; P Ling; N Einhorn; H Strander; J Wasserman
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Enhancement of defective monocyte function during immunotherapy with recombinant interferon.

Authors:  H Nielsen; P Ernst
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Augmentation of host defense by a unicellular green alga, Chlorella vulgaris, to Escherichia coli infection.

Authors:  K Tanaka; T Koga; F Konishi; M Nakamura; M Mitsuyama; K Himeno; K Nomoto
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

4.  Serum interferon activity in inflammatory bowel disease. Arachidonic acid release and lipoxygenation activated by alpha-class interferon in human neutrophils.

Authors:  O H Nielsen; J Elmgreen; I Ahnfelt-Rønne
Journal:  Inflammation       Date:  1988-04       Impact factor: 4.092

5.  Innate immunity during Equid herpesvirus 1 (EHV-1) infection.

Authors:  C G Bridges; N Edington
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.